• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Prometra micro-infusion device used to deliver meds directly to brain in epilepsy trial

March 15, 2017 By Sarah Faulkner

Prometra micro-infusion device used to deliver meds directly to brain in epilepsy trialFlowonix Medical and Cerebral Therapeutics said today that the 1st patients were implanted with the Prometra II programmable infusion system in a clinical trial evaluating the pump in patients with refractory epilepsy. The Address trial marks the 1st time a programmable, implantable pump has been used to deliver medication, in this case valproate, directly to the brain.

The Prometra micro-infusion device controls drug delivery to a region of the brain associated with medically refractory epilepsy.

The trial is slated to enroll 9 patients, who will receive intracerebroventricular administration of valproate using Flowonix’s programmable pump.

“We are really excited to be able to study this new treatment option for patients in the Address trial – it may offer new hope to those with uncontrolled epilepsy,” Mark Cook, chair of medicine & director of neurosciences at St. Vincent’s Hospital, said in prepared remarks.

Patients with refractory epilepsy do not respond to traditional medications and have higher mortality and a diminished quality of life compared to patients whose epilepsy is adequately controlled with drugs. Nearly 1 in 3 people with epilepsy develop refractory epilepsy, the companies said.

“The ability to target-deliver anti-epilepsy medication through an established infusion pump delivery could be a treatment with profoundly positive ramifications,” Dr. Ashwini Sharan, president of the North American Neuromodulation Society, said. “This is the 1st time in the world this approach is being taken.”

The Prometra device is FDA-approved for the intrathecal infusion of Infumorph, a perservative-free morphine sulfate sterile solution, or preservative-free sterile 0.9% saline solution.

“Neurological disorders can be devastating to patients and their families, who are often left with few options,” Flowonix CEO Larry Heaton said. “Flowonix is emerging as a world leader in implantable drug infusion systems used to treat pain, and we have particular expertise in the accurate and reliable delivery of microdoses of medication.”

“As the 1st trial of its kind, the Address study is a significant milestone for Flowonix Medical, Inc., Cerebral Therapeutics, the healthcare community, and patients worldwide. If the clinical study results in demonstrated positive outcomes, it would benefit patients who have refractory epilepsy and establish targeted drug delivery directly to the brain. It is gratifying when technological advancements offer such exciting possibilities for a new group of patients in need.”

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Neurological, Wall Street Beat Tagged With: Cerebral Therapeutics, Flowonix Medical

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS